Background High-dose therapy with supporting autologous stem-cell transplantation remains
a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating …

This presentation represents consensus recommendations for the clinicopathological definition
of Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the …

Background A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over
5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer …

Background Bisphosphonates reduce the risk of skeletal events in patients with malignant
bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and …

Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with
Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and …

… For instance, categorical response assessment at specific time points is influenced by M
protein type because clearance half lives vary considerably, typically 2 to 4 hours for free light …

Importance Numerous studies have evaluated the prognostic value of minimal residual
disease (MRD) in patients with multiple myeloma (MM). Most studies were small and varied in …

Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM)
after an initial response. This trial compared the effect of thalidomide maintenance and no …

… Bird,1 Roger G. Owen,2 Shirley D’Sa,3 John A. Snowden,4 Guy Pratt,5 John Ashcroft,2 Kwee
Yong,3 Gordon Cook,2 Sylvia Feyler,6 Faith Davies,7 Gareth Morgan,7 Jamie Cavenagh,8 …

The International Prognostic Index (IPI) identifies poor- and good-risk patients with diffuse
large B cell lymphoma (DLBCL); however, the majority of patients have an intermediate IPI, …